Investor Relations

2019 News Releases

Webcast ImageWebcast
Millendo Therapeutics, Inc. at Oppenheimer 29th Annual Healthcare Conference (Replay)
03/19/19 at 3:55 p.m. ET
Millendo Therapeutics, Inc. at Oppenheimer 29th Annual Healthcare Conference
Tuesday, March 19, 2019 3:55 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012
DateTitle  
03/19/19Millendo Therapeutics Initiates Pivotal Phase 2b/3 Clinical Study of Livoletide for the Treatment of Prader-Willi Syndrome
Top-line Phase 2b results are expected in 1H 2020 and may support an NDA submission for livoletide ANN ARBOR, Mich.--(BUSINESS WIRE)--Mar. 19, 2019-- Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced today that it has initiated its pivotal Phase 2b/3 clinical study investigating livoletide (AZP-531) in patients with Prader-Willi syn... 
 Printer Friendly Version
03/14/19Millendo Therapeutics Announces ENDO 2019 Presentations on Livoletide for Prader-Willi Syndrome and Nevanimibe for Classic Congenital Adrenal Hyperplasia
ANN ARBOR, Mich.--(BUSINESS WIRE)--Mar. 14, 2019-- Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced today that its clinical candidates, livoletide (AZP-531) and nevanimibe (ATR-101), will be featured in three poster presentations at ENDO 2019, taking place March 23-26, 2019 in New Orleans, La. Livoletide, a potential first-in-c... 
 Printer Friendly Version
03/04/19Millendo Therapeutics, Inc. to Present at the Cowen and Company 39th Annual Healthcare Conference and the Oppenheimer 29th Annual Healthcare Conference
ANN ARBOR, Mich.--(BUSINESS WIRE)--Mar. 4, 2019-- Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at two upcoming healthcare investor conferences. Details on the Presentations: Event: Cowen & Company 39th Annual Health Care ... 
 Printer Friendly Version
02/21/19Millendo Therapeutics, Inc. to Present at the 8th Annual SVB Leerink Global Healthcare Conference
ANN ARBOR, Mich.--(BUSINESS WIRE)--Feb. 21, 2019-- Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference in New York City on Thursday, February 28, 2019 at 11:30 a.m. EST. A live webcast of... 
 Printer Friendly Version
02/01/19Millendo Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich.--(BUSINESS WIRE)--Feb. 1, 2019-- Millendo Therapeutics, Inc. (“Millendo” or the “Company”) (NASDAQ: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced today that on January 28, 2019, the Compensation Committee of the Board of Directors approved, effective as of January 31, 2019, the grant of inducement stock options to purchase a total of 34,100 shares of the Comp... 
 Printer Friendly Version
01/17/19Millendo Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich.--(BUSINESS WIRE)--Jan. 17, 2019-- Millendo Therapeutics, Inc. (“Millendo” or the “Company”) (NASDAQ: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced today that on January 15, 2019, the Compensation Committee of the Board of Directors approved, effective as of January 15, 2019, the grant of inducement stock options to purchase a total of 51,200 shares of the Com... 
 Printer Friendly Version